Home

PAR-22-089 - Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)

On This Page: 4

Active NOSIs

Title Notice Number Organization Release
Date		 Expiration
Date		 Activity
Code(s)
Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) NOT-NS-23-062 NINDS Feb 6, 2023 Jun 24, 2024 R61/R33, R41/R42, R43/R44
Notice of Special Interest: Biomarker Discover and Validation in Functional Neurological Disorders NOT-NS-22-010 NINDS Oct 1, 2021 Jan 8, 2025 R61/R33, U01, U44

Expired NOSIs

Title Notice Number Organization Release
Date		 Expiration
Date		 Activity
Code(s)
Notice of Special Interest (NOSI) in Migraine and Headache Research NOT-NS-22-051 NINDS Dec 27, 2021 May 8, 2022 U01, K01, UG3/UH3, K22, K99/R00, K02, K08, R01, F30, K23, F32, R21, F31, R61/R33
Notice of Special Interest (NOSI) in NINDS mission relevant Pain Research NOT-NS-22-050 NINDS Dec 27, 2021 May 8, 2022 K01, UG3/UH3, K99/R00, K22, K08, R01, K02, F30, K23, R21, F32, F31, U01, U24, R61/R33


Technical Issues: E-mail OER Webmaster   




  • National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

  • NIH... Turning Discovery Into Health